Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker purchased 2,643 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The stock was bought at an average price of $5.82 per share, for a total transaction of $15,382.26. Following the purchase, the insider now owns 4,467,393 […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 38,304 shares of the stock in a transaction on Monday, June 6th. The stock was purchased at an average cost of $6.41 per share, with a total value of $245,528.64. Following the purchase, the insider now directly owns 4,501,658 shares of […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 16,849 shares of the stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $5.84 per share, for a total transaction of $98,398.16. Following the completion of the acquisition, the insider now owns 4,436,709 […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 7,837 shares of the stock in a transaction on Monday, May 23rd. The shares were acquired at an average cost of $5.99 per share, with a total value of $46,943.63. Following the purchase, the insider now owns 4,443,719 shares of the […]
Entrada Therapeutics (NASDAQ:TRDA – Get Rating) had its target price cut by equities research analysts at The Goldman Sachs Group from $22.00 to $10.00 in a report released on Tuesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside […]